Feb 27 (Reuters) – Flagship-backed Generate Biomedicines’ shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

An anonymous hacker group has reportedly breached the servers of a little-known Russian tech firm alleged to be involved in building the country’s unified military registration database. According to ...

I am a Backend Developer and Software Engineer with a solid background in Artificial Intelligence in academic and professional fields, looking forwa ...

The latest trends in software development from the Computer Weekly Application Developer Network. This is a guest post by Brian Sathianathan, chief technology officer and co-founder at Iterate.ai, ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Over the past few months, I have been helping developers and cloud professionals prepare for ...

The AEON Group holds “Pursuing peace, respecting humanity, and contributing to local communities, always with the customer's point of view as its core” as its foundational ideals, and operates ...